Quinupristin/Dalfopristin

Summary

Quinupristin/Dalfopristin (CHEMBL3137691) is a phase-3 clinical-stage unknown (ATC J01FG02); indicated across 3 conditions including bacterial infectious disease and gram-positive bacterial infections.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• ATC class: J01FG02
• Indications: 3 conditions
• Clinical trials: 1
• Chemistry: 1713.1 Da · C87H117N13O19S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3137691
Name	Quinupristin/Dalfopristin
Type	Unknown
Max phase	3
FDA approved	no
PubChem CID	71770713
ATC	J01FG02
Molecular formula	C87H117N13O19S2
Molecular weight	1713.1
InChIKey	PPKJUHVNTMYXOD-PZGPJMECSA-N

SMILES: CC[C@@H]1C(=O)N2CCC[C@H]2C(=O)N([C@H](C(=O)N3C[C@H](C(=O)C[C@H]3C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)CS[C@@H]6CN7CCC6CC7)CC8=CC=C(C=C8)N(C)C)C.CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@@H]([C@@H](/C=C/C(=O)NC/C=C/C(=C/[C@H](CC(=O)CC3=NC(=CO3)C2=O)O)/C)C)C(C)C

IUPAC name: N-[(3S,6S,12R,15S,16R,19S,22S,25R)-25-[[(3S)-1-azabicyclo[2.2.2]octan-3-yl]sulfanylmethyl]-3-[[4-(dimethylamino)phenyl]methyl]-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide;(6R,7S,10R,11R,12E,17E,19E,21S)-6-[2-(diethylamino)ethylsulfonyl]-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),12,17,19,25(28)-pentaene-2,8,14,23-tetrone

Also known as: Quinupristin/dalfopristin, Synercid, Quinupristin-dalfopristin, QUINUPRISTINE AND DALFOPRISTINE, QUINUPRISTIN/DALFOPRISTIN

Patent coverage: 37 distinct patent families (84 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
gram-positive bacterial infections	3	MONDO:0021679	MONDO:0021679
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00240747	PHASE3	TERMINATED	Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).